Insider Purchases: Inside the Buy
Tag: Mainz Biomed
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.